MX2021008326A - Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer. - Google Patents

Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer.

Info

Publication number
MX2021008326A
MX2021008326A MX2021008326A MX2021008326A MX2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A MX 2021008326 A MX2021008326 A MX 2021008326A
Authority
MX
Mexico
Prior art keywords
antibodies
tim
treatment
cancer
combinations
Prior art date
Application number
MX2021008326A
Other languages
English (en)
Inventor
Mythili Koneru
De Mendizabal Castillo Maria De Las Nieves Velez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021008326A publication Critical patent/MX2021008326A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a regímenes de dosificación para anticuerpos que se unen a la proteína 3 que contiene dominio de mucina e inmunoglobulina de células T (TIM-3) humana, y puede ser útil para tratar tumores en combinación con anticuerpos anti-PD-L1 humano, anticuerpos anti-PD-1 humano, quimioterapia y radiación ionizante, así como el uso de dichos anticuerpos para el tratamiento de tumores sólidos que son deficientes en la reparación de errores de apareamiento o exhiben un alto grado de inestabilidad de microsatélites.
MX2021008326A 2019-01-11 2020-01-03 Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer. MX2021008326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962791077P 2019-01-11 2019-01-11
PCT/US2020/012118 WO2020146196A1 (en) 2019-01-11 2020-01-03 Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021008326A true MX2021008326A (es) 2021-08-05

Family

ID=69423408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008326A MX2021008326A (es) 2019-01-11 2020-01-03 Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20220089740A1 (es)
EP (1) EP3908610A1 (es)
JP (1) JP2022517087A (es)
KR (1) KR20210102327A (es)
CN (1) CN113272331A (es)
AU (1) AU2020207132A1 (es)
BR (1) BR112021010703A2 (es)
CA (1) CA3126133A1 (es)
EA (1) EA202191526A1 (es)
IL (1) IL284320A (es)
MX (1) MX2021008326A (es)
WO (1) WO2020146196A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113866416B (zh) * 2021-10-20 2022-06-24 山东大学 可溶形式Tim3在免疫检查点阻断治疗抵抗的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
WO2017205213A1 (en) * 2016-05-23 2017-11-30 Eli Lilly And Company Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
AU2017354070A1 (en) 2016-11-01 2019-05-16 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (PD-1)
WO2018106529A1 (en) * 2016-12-08 2018-06-14 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
TWI793094B (zh) * 2017-01-09 2023-02-21 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法
EP3645037A1 (en) * 2017-06-27 2020-05-06 Novartis AG Dosage regimens for anti-tim-3 antibodies and uses thereof

Also Published As

Publication number Publication date
EA202191526A1 (ru) 2021-10-05
AU2020207132A1 (en) 2021-06-24
KR20210102327A (ko) 2021-08-19
BR112021010703A2 (pt) 2021-08-24
JP2022517087A (ja) 2022-03-04
EP3908610A1 (en) 2021-11-17
WO2020146196A1 (en) 2020-07-16
CA3126133A1 (en) 2020-07-16
US20220089740A1 (en) 2022-03-24
IL284320A (en) 2021-08-31
CN113272331A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12020500075A1 (en) Checkpoint inhibitor bispecific antibodies
JOP20200292A1 (ar) Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
PH12019500369A1 (en) Anti-tim-3 antibodies
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
MY195110A (en) Antibodies to PD-1 and uses Thereof
JOP20180040A1 (ar) مثبطات pd-1/pd-l1
JOP20210314A1 (ar) Tigit وجزيئات ربط pd-1/tigit
EA202190181A1 (ru) Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
JOP20200016B1 (ar) أجسام مضادة لـ cd137
WO2019036031A3 (en) Immunotherapeutic tumor treatment method
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
MX2022004766A (es) Terapias combinadas con venetoclax e inhibidores de tim-3.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
MX2018009621A (es) Combinaciones de dihidrocloruro de histamina y uso de estas.
MX2021008326A (es) Anticuerpos contra tim-3 y combinaciones con otros inhibidores de puntos de regulacion para el tratamiento del cancer.
MX2021011034A (es) Metodos y composiciones para el tratamiento del cancer.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2023007780A (es) Terapia de combinacion usando un anticuerpo anti-fucosil-gm1.
EA202092733A1 (ru) Ингибиторы pd-1/pd-l1
EA201992045A1 (ru) Ингибиторы pd-1/pd-l1